drugset / Trial / NCT00768755

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

NCT00768755

Phase 1/2 Completed 180 enrolled Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).

Timeline

Start
2009-01
Primary completion
2011-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 10 mg Oral
Comparator Cisplatin Other / unclassified 75 mg/m2
Comparator Pemetrexed Small molecule 500 mg/m2